Extracorporeal shock wave lithotripsy with a transportable electrohydraulic lithotripter: Experience with >300 patients

David M. Albala, Khurram M. Siddiqui, Brant Fulmer, Joseph Alioto, Jeffery Frankel, Manoj Monga

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: To review a multicentre experience of using a transportable lithotripter (STS-T, Medstone, Inc, Aliso Viejo, CA. USA) for treating patients with urolithiasis in all parts of the urinary tract. PATIENTS AND METHODS: In all, 326 patients with a total of 370 stones were treated as outpatients with the STS-T lithotripter. All patients received a single shock wave lithotripsy treatment and were followed after 4-6 weeks in the outpatient clinic, the primary endpoint being to determine the efficacy (as defined by the stone-free rate). Secondary objectives included establishing a database of patient demographic information, stone characteristics, stone location, procedural endpoints, and complication rates. RESULTS: In all there were 370 procedures, with a mean of 2394 shocks administered at an energy level of 24 kV. The mean treatment time was 51 min, excluding anaesthesia-induction time. The mean stone aggregate size was 8.2 mm; 62% of the stones were in the kidney while 38% were in various locations in the ureter. Of the treated stones, 90% had definite or probable evidence of fragmentation. The overall stone-free rate after one treatment with the STS-T was 52.8%. Of patients with residual fragments, most (61%) had fragments of <4 mm in aggregate diameter. The overall complication rate was 3.8%, the most common complication being postoperative pain. CONCLUSION: The Medstone STS-T lithotripter was an effective device for treating urolithiasis in all parts of the urinary tract. This system had a high margin of safety, as shown by the low complication rate. With no apparent sacrifice of efficacy compared to first-generation or fixed (not transportable) second-generation devices, the Medstone STS-T represents an important advance in the development of a truly transportable lithotripter.

Original languageEnglish
Pages (from-to)603-607
Number of pages5
JournalBJU International
Volume96
Issue number4
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Lithotripsy
Urolithiasis
Urinary Tract
Equipment and Supplies
Ureter
Postoperative Pain
Ambulatory Care Facilities
Shock
Outpatients
Therapeutics
Anesthesia
Demography
Databases
Kidney
Safety

Keywords

  • ESWL
  • Lithotripter
  • Outcome
  • Spark gap lithotripsy
  • Stones
  • Urolithiasis

ASJC Scopus subject areas

  • Urology

Cite this

Extracorporeal shock wave lithotripsy with a transportable electrohydraulic lithotripter : Experience with >300 patients. / Albala, David M.; Siddiqui, Khurram M.; Fulmer, Brant; Alioto, Joseph; Frankel, Jeffery; Monga, Manoj.

In: BJU International, Vol. 96, No. 4, 09.2005, p. 603-607.

Research output: Contribution to journalArticle

Albala, David M. ; Siddiqui, Khurram M. ; Fulmer, Brant ; Alioto, Joseph ; Frankel, Jeffery ; Monga, Manoj. / Extracorporeal shock wave lithotripsy with a transportable electrohydraulic lithotripter : Experience with >300 patients. In: BJU International. 2005 ; Vol. 96, No. 4. pp. 603-607.
@article{501dd5272eb540de9f65acc30ca353cb,
title = "Extracorporeal shock wave lithotripsy with a transportable electrohydraulic lithotripter: Experience with >300 patients",
abstract = "OBJECTIVE: To review a multicentre experience of using a transportable lithotripter (STS-T, Medstone, Inc, Aliso Viejo, CA. USA) for treating patients with urolithiasis in all parts of the urinary tract. PATIENTS AND METHODS: In all, 326 patients with a total of 370 stones were treated as outpatients with the STS-T lithotripter. All patients received a single shock wave lithotripsy treatment and were followed after 4-6 weeks in the outpatient clinic, the primary endpoint being to determine the efficacy (as defined by the stone-free rate). Secondary objectives included establishing a database of patient demographic information, stone characteristics, stone location, procedural endpoints, and complication rates. RESULTS: In all there were 370 procedures, with a mean of 2394 shocks administered at an energy level of 24 kV. The mean treatment time was 51 min, excluding anaesthesia-induction time. The mean stone aggregate size was 8.2 mm; 62{\%} of the stones were in the kidney while 38{\%} were in various locations in the ureter. Of the treated stones, 90{\%} had definite or probable evidence of fragmentation. The overall stone-free rate after one treatment with the STS-T was 52.8{\%}. Of patients with residual fragments, most (61{\%}) had fragments of <4 mm in aggregate diameter. The overall complication rate was 3.8{\%}, the most common complication being postoperative pain. CONCLUSION: The Medstone STS-T lithotripter was an effective device for treating urolithiasis in all parts of the urinary tract. This system had a high margin of safety, as shown by the low complication rate. With no apparent sacrifice of efficacy compared to first-generation or fixed (not transportable) second-generation devices, the Medstone STS-T represents an important advance in the development of a truly transportable lithotripter.",
keywords = "ESWL, Lithotripter, Outcome, Spark gap lithotripsy, Stones, Urolithiasis",
author = "Albala, {David M.} and Siddiqui, {Khurram M.} and Brant Fulmer and Joseph Alioto and Jeffery Frankel and Manoj Monga",
year = "2005",
month = "9",
doi = "10.1111/j.1464-410X.2005.05692.x",
language = "English",
volume = "96",
pages = "603--607",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Extracorporeal shock wave lithotripsy with a transportable electrohydraulic lithotripter

T2 - Experience with >300 patients

AU - Albala, David M.

AU - Siddiqui, Khurram M.

AU - Fulmer, Brant

AU - Alioto, Joseph

AU - Frankel, Jeffery

AU - Monga, Manoj

PY - 2005/9

Y1 - 2005/9

N2 - OBJECTIVE: To review a multicentre experience of using a transportable lithotripter (STS-T, Medstone, Inc, Aliso Viejo, CA. USA) for treating patients with urolithiasis in all parts of the urinary tract. PATIENTS AND METHODS: In all, 326 patients with a total of 370 stones were treated as outpatients with the STS-T lithotripter. All patients received a single shock wave lithotripsy treatment and were followed after 4-6 weeks in the outpatient clinic, the primary endpoint being to determine the efficacy (as defined by the stone-free rate). Secondary objectives included establishing a database of patient demographic information, stone characteristics, stone location, procedural endpoints, and complication rates. RESULTS: In all there were 370 procedures, with a mean of 2394 shocks administered at an energy level of 24 kV. The mean treatment time was 51 min, excluding anaesthesia-induction time. The mean stone aggregate size was 8.2 mm; 62% of the stones were in the kidney while 38% were in various locations in the ureter. Of the treated stones, 90% had definite or probable evidence of fragmentation. The overall stone-free rate after one treatment with the STS-T was 52.8%. Of patients with residual fragments, most (61%) had fragments of <4 mm in aggregate diameter. The overall complication rate was 3.8%, the most common complication being postoperative pain. CONCLUSION: The Medstone STS-T lithotripter was an effective device for treating urolithiasis in all parts of the urinary tract. This system had a high margin of safety, as shown by the low complication rate. With no apparent sacrifice of efficacy compared to first-generation or fixed (not transportable) second-generation devices, the Medstone STS-T represents an important advance in the development of a truly transportable lithotripter.

AB - OBJECTIVE: To review a multicentre experience of using a transportable lithotripter (STS-T, Medstone, Inc, Aliso Viejo, CA. USA) for treating patients with urolithiasis in all parts of the urinary tract. PATIENTS AND METHODS: In all, 326 patients with a total of 370 stones were treated as outpatients with the STS-T lithotripter. All patients received a single shock wave lithotripsy treatment and were followed after 4-6 weeks in the outpatient clinic, the primary endpoint being to determine the efficacy (as defined by the stone-free rate). Secondary objectives included establishing a database of patient demographic information, stone characteristics, stone location, procedural endpoints, and complication rates. RESULTS: In all there were 370 procedures, with a mean of 2394 shocks administered at an energy level of 24 kV. The mean treatment time was 51 min, excluding anaesthesia-induction time. The mean stone aggregate size was 8.2 mm; 62% of the stones were in the kidney while 38% were in various locations in the ureter. Of the treated stones, 90% had definite or probable evidence of fragmentation. The overall stone-free rate after one treatment with the STS-T was 52.8%. Of patients with residual fragments, most (61%) had fragments of <4 mm in aggregate diameter. The overall complication rate was 3.8%, the most common complication being postoperative pain. CONCLUSION: The Medstone STS-T lithotripter was an effective device for treating urolithiasis in all parts of the urinary tract. This system had a high margin of safety, as shown by the low complication rate. With no apparent sacrifice of efficacy compared to first-generation or fixed (not transportable) second-generation devices, the Medstone STS-T represents an important advance in the development of a truly transportable lithotripter.

KW - ESWL

KW - Lithotripter

KW - Outcome

KW - Spark gap lithotripsy

KW - Stones

KW - Urolithiasis

UR - http://www.scopus.com/inward/record.url?scp=24044503060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044503060&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2005.05692.x

DO - 10.1111/j.1464-410X.2005.05692.x

M3 - Article

C2 - 16104918

AN - SCOPUS:24044503060

VL - 96

SP - 603

EP - 607

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 4

ER -